Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos


The addition of AAP to enzalutamide for first-line treatment of mCRPC was not associated with a statistically significant benefit in OS. Drug-drug interactions between the two agents resulting in increased abiraterone clearance may partly account for this result, although these interactions did not …

  • 123456 Profile photo of Madelyn

    Do you combine enzalutamide and abiraterone/prednisone? You should not. phase 3 trial showing no benefit.